SCHEMBL27162476

SCHEMBL27162476

CC(C)(C)CN1CCCC2(CCN(S(=O)(=O)c3ccc(N4CCOC4=O)nc3)CC2)C1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 10/20 0.42
▸ TSHR P16473 7/20 0.42
▸ CYP2C19 P33261 7/20 0.42
▸ USP2 O75604 4/20 0.42
▸ CYP2D6 P10635 8/20 0.41
▸ ALDH1A1 P00352 7/20 0.40
▸ CYP1A2 P05177 5/20 0.40
▸ CYP2C9 P11712 5/20 0.40
▸ GAA P10253 3/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ SMN1; SMN2 Q16637 4/20 0.39
▸ KCNJ1 P48048 2/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ LMNA P02545 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30050972 1.00 CYP3A4 (0.42) CYP3A4TSHRCYP2C19USP2CYP2D6
SCHEMBL30049755 0.91 CYP3A4 (0.41) CYP3A4TSHRCYP2C19USP2CYP2D6
SCHEMBL27162570 0.91 CYP3A4 (0.41) CYP3A4TSHRCYP2C19USP2CYP2D6
SCHEMBL30049333 0.90 ALDH1A1 (0.42) CYP3A4TSHRUSP2CYP2D6ALDH1A1
SCHEMBL27161892 0.90 ALDH1A1 (0.42) CYP3A4TSHRUSP2CYP2D6ALDH1A1
SCHEMBL30050997 0.85 CYP2D6 (0.62) CYP3A4TSHRCYP2C19USP2CYP2D6
SCHEMBL27162156 0.85 CYP2D6 (0.62) CYP3A4TSHRCYP2C19USP2CYP2D6
SCHEMBL30051175 0.84 TSHR (0.39) CYP3A4TSHRCYP2C19USP2CYP2D6
SCHEMBL27161927 0.84 TSHR (0.39) CYP3A4TSHRCYP2C19USP2CYP2D6
SCHEMBL30050090 0.84 SMN1; SMN2 (0.42) CYP3A4TSHRCYP2C19USP2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US claimed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP claimed
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US disclosed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands SIGMAR1, TMEM97, OPRD1 CYP3A4 497/4885TSHR 540/4885CYP2C19 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback